Shiny Quarter at Illumina

Illumina ( ILMN), a developer of genetic-testing tools, saw its shares jump more than 18% after the company's quarterly earnings report came in much stronger than expected Tuesday.

The San Diego-based company reported earnings and revenue that blew past estimates thanks to a number of recent deals it signed, including arrangements with deCode Genetics ( DCGN) of Iceland, the Children's Hospital of Philadelphia and the Center for Children with Special Needs in Qatar.

Illumina reported second-quarter revenue of $41.6 million, more than double last year. The company earned $6.8 million, or 14 cents a share, reversing a loss of $18.5 million, or 46 cents a share, in the year-ago quarter.

Excluding certain charges, Illumina would have earned $10.1 million, or 21 cents a share. Analysts surveyed by Thomson First Call expected the company to earn 3 cents a share with a top line of just under $33 million. Shares of Ilumina were surging $5.23 to $33.55 in after-hours trading.

Thanks to strong demand for the company's genotyping technologies, Illumina raised its third-quarter revenue guidance to between $44 million and $48 million and its profit forecast to 22 cents to 24 cents a share, before items. Analysts had been predicting revenue of $36 million and earnings of 4 cents a share.

For the full year, the company expects revenue of between $160 million and $170 million and earnings, excluding any items, of 61 cents to 82 cents a share.

More from Stocks

Market Movers: Tech Earnings

Market Movers: Tech Earnings

Cloud Gaming Adds Growth Opportunity for Microsoft

Cloud Gaming Adds Growth Opportunity for Microsoft

Dow Dives Sharply on Rates Fears, Tech Shares Sink Nasdaq

Dow Dives Sharply on Rates Fears, Tech Shares Sink Nasdaq

Throwback Thursday: To Trade or Not to Trade Paypal

Throwback Thursday: To Trade or Not to Trade Paypal

Daimler's Going Autonomous With Nvidia to Take On Uber, Ride-Hailing Race

Daimler's Going Autonomous With Nvidia to Take On Uber, Ride-Hailing Race